Helix BioPharma Cash Per Share vs. Total Debt
| HBP Stock | CAD 0.79 0.05 5.95% |
Cash Per Share | First Reported 2010-12-31 | Previous Quarter 0.02429983 | Current Value 0.0231 | Quarterly Volatility 0.40294973 |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.69 | 0.68 |
|
|
For Helix BioPharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Helix BioPharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Helix BioPharma Corp utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Helix BioPharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Helix BioPharma Corp over time as well as its relative position and ranking within its peers.
Helix |
Helix BioPharma Corp Total Debt vs. Cash Per Share Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Helix BioPharma's current stock value. Our valuation model uses many indicators to compare Helix BioPharma value to that of its competitors to determine the firm's financial worth. Helix BioPharma Corp is rated # 5 in cash per share category among its peers. It also is rated # 5 in total debt category among its peers making up about 157,900,000 of Total Debt per Cash Per Share. At this time, Helix BioPharma's Cash Per Share is very stable compared to the past year. Comparative valuation analysis is a catch-all model that can be used if you cannot value Helix BioPharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Helix BioPharma's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Helix Total Debt vs. Cash Per Share
Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Helix BioPharma |
| = | 0.01 X |
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Helix BioPharma |
| = | 1.58 M |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Helix Total Debt vs Competition
Helix BioPharma Corp is rated # 5 in total debt category among its peers. Total debt of Health Care industry is currently estimated at about 82.88 Million. Helix BioPharma claims roughly 1.58 Million in total debt contributing just under 2% to equities under Health Care industry.
Helix BioPharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Helix BioPharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Helix BioPharma will eventually generate negative long term returns. The profitability progress is the general direction of Helix BioPharma's change in net profit over the period of time. It can combine multiple indicators of Helix BioPharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 5 M | 2.8 M | |
| Operating Income | -9.4 M | -9.8 M | |
| Income Before Tax | -9.4 M | -9.9 M | |
| Total Other Income Expense Net | -25 K | -26.2 K | |
| Net Loss | -9.3 M | -9.7 M | |
| Income Tax Expense | -132 K | -138.6 K | |
| Net Loss | -9.3 M | -9.7 M | |
| Net Loss | -7.2 M | -7.6 M | |
| Interest Income | 35.6 K | 37 K | |
| Net Interest Income | 24 K | 25.2 K | |
| Change To Netincome | 840.6 K | 882.6 K | |
| Net Loss | (0.21) | (0.22) | |
| Income Quality | 0.56 | 0.73 | |
| Net Income Per E B T | 1.13 | 1.03 |
Helix Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Helix BioPharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Helix BioPharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Helix BioPharma's important profitability drivers and their relationship over time.
Use Helix BioPharma in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Helix BioPharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Helix BioPharma will appreciate offsetting losses from the drop in the long position's value.Helix BioPharma Pair Trading
Helix BioPharma Corp Pair Trading Analysis
The ability to find closely correlated positions to Helix BioPharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Helix BioPharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Helix BioPharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Helix BioPharma Corp to buy it.
The correlation of Helix BioPharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Helix BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Helix BioPharma Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Helix BioPharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Helix BioPharma position
In addition to having Helix BioPharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Chemicals Makers Thematic Idea Now
Chemicals Makers
Companies developing chemicals for crops, soil as well as human, and animals. The Chemicals Makers theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Chemicals Makers Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Helix Stock
To fully project Helix BioPharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Helix BioPharma Corp at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Helix BioPharma's income statement, its balance sheet, and the statement of cash flows.